NĒRx BioSciences
2 known investors
NĒRx Biosciences is a pre-clinical stage biotechnology company developing targeted anticancer therapeutics focused on the DNA damage response (DDR) and DNA repair. Its approach targets the proteins that detect DNA damage (DDR sensors) rather than the kinases that react to them, aiming to improve patient response and survival.
Investors · 2
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $293K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2015 | $299.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $299.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2012 | $229.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does NĒRx BioSciences do?
- NĒRx Biosciences is a pre-clinical stage biotechnology company developing targeted anticancer therapeutics focused on the DNA damage response (DDR) and DNA repair. Its approach targets the proteins that detect DNA damage (DDR sensors) rather than the kinases that react to them, aiming to improve patient response and survival.
- Who are NĒRx BioSciences's investors?
- NĒRx BioSciences's investors include Elevate Ventures, IU Ventures.